Genticel
Develops therapeutic vaccines for the prevention of cervical cancer in HPV infected women.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
N/A | Merger | ||
| Total Funding | 000k | ||
| EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | (92 %) | 50 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (6383 %) | - | - | (564 %) | (4726 %) | (3492 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (6288 %) | - | - | (654 %) | (5073 %) | (6601 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 4489 % | - | - | 534 % | 3738 % | 2174 % |
Source: Company filings or news article
Related Content
Genkyotex is a biotechnology company specializing in the development of NOX enzyme inhibitors to treat chronic diseases and enhance immunotherapy. Operating in the biopharmaceutical market, Genkyotex primarily serves patients with conditions such as primary biliary cholangitis (PBC) and other fibrotic and inflammatory diseases. The company's business model revolves around research and development, clinical trials, and eventual commercialization of its proprietary compounds. Revenue is generated through partnerships, licensing agreements, and potential future sales of approved therapies.
Genkyotex's innovative approach focuses on inhibiting NOX enzymes, which play a critical role in the progression of various diseases, thereby offering a novel therapeutic pathway.
Keywords: NOX enzyme inhibitors, immunotherapy, chronic diseases, biotechnology, biopharmaceutical, primary biliary cholangitis, fibrotic diseases, inflammatory diseases, clinical trials, proprietary compounds.
Investments by Genticel
Edit